BioCentury | Aug 16, 2018
Distillery Therapeutics

Neurology

...GmbH has the P2RX7 antagonist AFC-5128 in preclinical testing for neuropathic pain and multiple sclerosis. RaQualia Pharma Inc....
BioCentury | Jul 10, 2018
Distillery Therapeutics

Neurology

...TRPM8 antagonist in preclinical testing for interstitial cysitis, urinary tract disorders and overactive bladder (OAB). RaQualia Pharma Inc....
BioCentury | Apr 27, 2018
Emerging Company Profile

Cinclus’ acid inhibition

...At least two other P-CABs are also in the clinic for GERD: tegoprazan (RQ-04) from RaQualia Pharma Inc....
...Daewoong Pharmaceutical Co. Ltd. (KSE:069620), Seoul, South Korea Jiangsu Sinorda Biomedicine Co. Ltd., Suzhou, China RaQualia Pharma Inc....
BioCentury | Jan 5, 2018
Company News

RaQualia, Maruho in deal for sodium channel blocker

...Osaka, Japan) exclusive, worldwide rights to develop and commercialize an undisclosed selective sodium channel blocker. RaQualia...
...disclose details. RaQualia Pharma Inc. (JASDAQ:4579), Nagoya, Japan Maruho Co. Ltd., Osaka, Japan Business: Neurology Chris Lieu Maruho Co. Ltd. RaQualia Pharma Inc....
BioCentury | Aug 4, 2016
Finance

2Q16 Public-Private Partnership Roundup

...develop potential clinical applications of induced pluripotent stem (iPS) cells. 11/18/2015 RaQualia Pharma Inc. (JASDAQ:4579) Nagoya University RaQualia...
BioCentury | Apr 4, 2016
Company News

Asahi Kasei Pharma, RaQualia deal

...pain compounds targeting an undisclosed ion channel. The partners will use RaQualia’s drug development technology. RaQualia...
...BioCentury, Nov. 25, 2013 & April 14, 2014). Asahi Kasei Pharma Corp. , Tokyo, Japan RaQualia Pharma Inc....
BioCentury | Jan 11, 2016
Company News

RaQualia, Sihuan deal

...share income from other markets with RaQualia. The companies could not be reached for details. RaQualia Pharma Inc....
BioCentury | Dec 14, 2015
Company News

CJ, Shandong Luoxin Pharmaceutical Group deal

...gastrointestinal diseases. CJ has rights to the product in several Asian countries, including China, from RaQualia Pharma Inc....
BioCentury | Nov 20, 2015
Company News

Ipsen, Interprotein in endocrine disease deal

...structure-based drug discovery platforms to design therapeutics targeting protein-protein interactions. In 2013, it partnered with RaQualia Pharma Inc....
BioCentury | Aug 3, 2015
Company News

RaQualia, Durata Therapeutics deal

...to regain Japanese rights to dalbavancin from Allergan plc (NYSE:AGN, Dublin, Ireland). In December 2010, RaQualia...
...skin structure infections (ABSSSIs) in adults (see BioCentury, May 2, 2011 & Nov. 24, 2014). RaQualia Pharma Inc....
Items per page:
1 - 10 of 81
BioCentury | Aug 16, 2018
Distillery Therapeutics

Neurology

...GmbH has the P2RX7 antagonist AFC-5128 in preclinical testing for neuropathic pain and multiple sclerosis. RaQualia Pharma Inc....
BioCentury | Jul 10, 2018
Distillery Therapeutics

Neurology

...TRPM8 antagonist in preclinical testing for interstitial cysitis, urinary tract disorders and overactive bladder (OAB). RaQualia Pharma Inc....
BioCentury | Apr 27, 2018
Emerging Company Profile

Cinclus’ acid inhibition

...At least two other P-CABs are also in the clinic for GERD: tegoprazan (RQ-04) from RaQualia Pharma Inc....
...Daewoong Pharmaceutical Co. Ltd. (KSE:069620), Seoul, South Korea Jiangsu Sinorda Biomedicine Co. Ltd., Suzhou, China RaQualia Pharma Inc....
BioCentury | Jan 5, 2018
Company News

RaQualia, Maruho in deal for sodium channel blocker

...Osaka, Japan) exclusive, worldwide rights to develop and commercialize an undisclosed selective sodium channel blocker. RaQualia...
...disclose details. RaQualia Pharma Inc. (JASDAQ:4579), Nagoya, Japan Maruho Co. Ltd., Osaka, Japan Business: Neurology Chris Lieu Maruho Co. Ltd. RaQualia Pharma Inc....
BioCentury | Aug 4, 2016
Finance

2Q16 Public-Private Partnership Roundup

...develop potential clinical applications of induced pluripotent stem (iPS) cells. 11/18/2015 RaQualia Pharma Inc. (JASDAQ:4579) Nagoya University RaQualia...
BioCentury | Apr 4, 2016
Company News

Asahi Kasei Pharma, RaQualia deal

...pain compounds targeting an undisclosed ion channel. The partners will use RaQualia’s drug development technology. RaQualia...
...BioCentury, Nov. 25, 2013 & April 14, 2014). Asahi Kasei Pharma Corp. , Tokyo, Japan RaQualia Pharma Inc....
BioCentury | Jan 11, 2016
Company News

RaQualia, Sihuan deal

...share income from other markets with RaQualia. The companies could not be reached for details. RaQualia Pharma Inc....
BioCentury | Dec 14, 2015
Company News

CJ, Shandong Luoxin Pharmaceutical Group deal

...gastrointestinal diseases. CJ has rights to the product in several Asian countries, including China, from RaQualia Pharma Inc....
BioCentury | Nov 20, 2015
Company News

Ipsen, Interprotein in endocrine disease deal

...structure-based drug discovery platforms to design therapeutics targeting protein-protein interactions. In 2013, it partnered with RaQualia Pharma Inc....
BioCentury | Aug 3, 2015
Company News

RaQualia, Durata Therapeutics deal

...to regain Japanese rights to dalbavancin from Allergan plc (NYSE:AGN, Dublin, Ireland). In December 2010, RaQualia...
...skin structure infections (ABSSSIs) in adults (see BioCentury, May 2, 2011 & Nov. 24, 2014). RaQualia Pharma Inc....
Items per page:
1 - 10 of 81